Cybin Inc.

CYBN

CA23256X1006

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			After market 06:30:14 pm
0.35 ^USD	+1.16%		0.346	-1.14%

Apr. 17	Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	MT
Apr. 16	Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	MT

Cybin Inc. announced that it has received $150 million in funding from a group of investors

March 18, 2024

On March 19, 2024, Cybin Inc. closed the transaction. The company raised $108,699,999 pursuant to Regulation D in the transaction from 12 investors.

Latest news about Cybin Inc.

Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	Apr. 17	MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	Apr. 16	MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors	Mar. 18	CI
Sector Update: Health Care Stocks Softer Friday Afternoon	Mar. 15	MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	Mar. 15	MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	Mar. 15	CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	Mar. 14	MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	Mar. 14	CI
Sector Update: Health Care Stocks Ease Wednesday Afternoon	Mar. 13	MT
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump	Mar. 13	MT
Transcript : Cybin Inc. - Special Call	Mar. 13
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder	Mar. 13	CI
Cybin Inc. announced that it expects to receive $150 million in funding	Mar. 12	CI
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study	Jan. 23	MT
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder	Jan. 23	CI
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028	Jan. 08	CI
Cybin Inc. Announces Recent Positive Phase 2 CYB003 Topline Results in MDD and Outlines Key Upcoming Milestones Across its Clinical Development Programs	Jan. 04	CI
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting	Dec. 06	CI
Transcript : Cybin Inc. - Special Call	Nov. 30
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses	Nov. 30	CI
HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating	Nov. 17	MT
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Transcript : Cybin Inc. - Special Call	Nov. 01
Cybin Inc. Provides Update on its Clinical-Stage Programs and Key Upcoming Milestones Across its Development Pipeline	Nov. 01	CI

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Milken Institute Global Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4791 CAD

Average target price

6.568 CAD

Spread / Average Target

+1,270.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYBIN INC.	-14.63%	266M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Cybin Inc.

Equities

CYBN

CA23256X1006

Biotechnology & Medical Research

Cybin Inc. announced that it has received $150 million in funding from a group of investors

Latest news about Cybin Inc.

Chart Cybin Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs